Decentralized Clinical Trials: How To Deliver The Complex Efficiently

COVID-19 has had a huge impact on the clinical trials environment. “On 18 March, Addex announced that it would delay the start of a clinical trial to treat involuntary movements in people with Parkinson’s disease. The following week, the pharmaceutical giant Eli Lilly in Indianapolis, Indiana, announced that it would halt enrollment in ongoing studies and delay the launch of new trials.” (Ledford, H 2020). The COVID-19 pandemic has clearly highlighted the weaknesses of the traditional site centric clinical trial designs. Read how decentralized clinical trials may be the solution.